What Phenox does

Phenox GmbH is a privately held German medical device company headquartered in Bochum, founded in 2005, that develops and commercializes neurovascular devices for the treatment of ischemic stroke and cerebral aneurysms. The company sells three core product families — the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal; the pEGASUS self-expanding open-cell stent system for wide-neck aneurysms, dissections, and intracranial stenoses; and the Avenir Coil System, which is manufactured by Wallaby Medical and distributed by phenox — all carrying CE Mark approval (CE 0297 and CE 2797) for European and international markets but not approved for sale in the United States. Differentiated proprietary technology includes HPC (Hydrophilic Polymer Coating), an antithrombogenic coating now supported by the COATING Randomized Controlled Trial demonstrating safety with Single Antiplatelet Therapy, and the pRESET device's helical slit and dual-type cell design for first-pass thrombectomy success.

Phenox operates a direct enterprise sales model targeting hospitals and ambulatory surgical centers with interventional neuroradiology departments, with revenue generated through hardware device sales. The company maintains clinical evidence leadership via the PROST trial published in JAMA Neurology (2024) and the COATING trial published in JNIS (2025), and has received non-dilutive R&D funding from European and German government programs (EFRE NRW, EU, BMBF, Bundes-ESF). Commercial operations appear commercially linked to Wallaby Medical through shared "WallabyPhenox" branding and the wallabyphenox.com marketing domain, suggesting a deeper commercial relationship than a standalone distributor arrangement, though the precise ownership structure is not publicly disclosed. The company has 101–250 employees and is led by CEO James Lago, founder Hermann Monstadt, and CFO Attila Kravecz, with only one known institutional venture funding event (SHS Capital, 2010).

Name

Phenox

Legal name

phenox GmbH

Website

http://www.phenox.net/

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Phenox GmbH is a Bochum, Germany-based private medical device company that develops and sells CE-marked neurovascular devices — including the pRESET thrombectomy, pEGASUS stent, and Avenir coil systems — to hospitals and ambulatory surgical centers for ischemic stroke and aneurysm treatment in markets outside the United States.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Neurovascular medical devices
• Thrombectomy devices
• Aneurysm treatment systems
• Ischemic stroke intervention
• Flow diversion stents

Headquarters

HQ city

Bochum

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: phenox generates revenue through the sale of neurovascular medical devices including the pRESET thrombectomy devices, pEGASUS stent systems, and distributed Avenir coil systems. Products are sold directly to hospitals and healthcare facilities with CE Mark approval for European and international markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Phenox develops, manufactures, and distributes CE Mark-certified neurovascular medical devices for the treatment of cerebral aneurysms and ischemic stroke. Its core product portfolio includes the pRESET family of stent retriever thrombectomy devices (pRESET, pRESET LITE, pRESET LUX) for mechanical clot removal, the pEGASUS self-expanding stent system for wide-neck aneurysms and intracranial stenoses, and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. Devices are sold through direct sales relationships with hospitals and ambulatory surgical centers internationally.

Product overview

Phenox is a medical device company specializing in neurovascular treatments for ischemic stroke and aneurysm treatment. The product portfolio centers on three core device families: the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal in acute ischemic stroke; the pEGASUS Stent System for wide-neck aneurysm, dissection, and intracranial stenosis treatment; and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. These devices are offered with optional HPC (Hydrophilic Polymer Coating) technology for enhanced thrombogenicity profiles. All products carry CE Mark certification and are not approved for sale in the United States.

Differentiator

Problem solved

Functional benefit

Brands

• pRESET: Thrombectomy device for ischemic stroke treatment, including pRESET 4-20, 5-40, 6-30 for proximal treatment and pRESET LITE 3-20, 4-20 for distal treatment, and pRESET LUX with visible HPC coating.
• pEGASUS
• Avenir Wallaby

Products and services

• pRESET Thrombectomy Device Stent retriever thrombectomy device for mechanical clot removal in acute ischemic stroke treatment. Features helical slit design with dual type cell architecture for deep clot integration and flexibility in tortuous anatomies. Available in sizes 4-20, 5-40, 6-30, and 6-50 for large thrombus load in proximal treatment locations. CE Mark certified (CE 0297).
• pRESET LITE Thrombectomy Device Distal treatment variant of the pRESET thrombectomy device, designed for smaller vessels with sizes 3-20 and 4-20 for treating distal thrombus locations in acute ischemic stroke. CE Mark certified (CE 0297).
• pRESET LUX Thrombectomy Device pRESET variant featuring full visibility through NAC (Noble Alloy Coating) on the full length of the device, designed for first-pass success in proximal thrombus treatment. CE Mark certified (CE 0297).
• pEGASUS Stent System Self-expanding, open-cell stent designed for treatment of wide-neck aneurysms, dissections, and intracranial stenoses. Features optimal adaptation to different vessel configurations for vessels from 2.5mm to 4.5mm, and is available with optional antithrombogenic HPC (Hydrophilic Polymer Coating) technology.
• Avenir Coil System Coil embolization system for aneurysm treatment manufactured by Wallaby Medical and distributed by phenox GmbH. Available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling configurations with ultra-soft 0.0013 inch primary wire for enhanced conformability and packing density, featuring an instant detachment mechanism. CE Mark certified (CE 2797).

Quantifiable outcome

• HPC-coated flow diverters proven safe for use with Single Antiplatelet Therapy (SAPT) based on COATING RCT 1-month safety results published in JNIS 2025
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Wallaby MedicalcoreTechnology or IntegrationWallaby Medical manufactures the Avenir Coil System (CE 2797), which is distributed by phenox GmbH. The Avenir is available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling versions. This partnership allows phenox to offer a comprehensive coil embolization solution as part of their neurovascular treatment portfolio.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Rapid Medical: Rapid Medical is an Israeli neurovascular device company developing stent retrievers, distal access catheters, and flow diverters for stroke and aneurysm treatment. It competes head-to-head with Phenox across the neurointerventional procedure workflow in CE Mark and select global markets.
• Penumbra: Penumbra is a US-based neurovascular and vascular thrombectomy company that directly competes with Phenox's pRESET stent retriever in mechanical thrombectomy for acute ischemic stroke. Both companies serve hospitals and interventional neuroradiology departments with hardware-based clot retrieval solutions.
• Wallaby Medical: Wallaby Medical manufactures the Avenir Coil System distributed by Phenox and appears closely affiliated with Phenox under the wallabyphenox.com brand. Both companies serve the neurovascular aneurysm and stroke markets with complementary coil and stent retriever technologies.
• Acandis: Acandis is a German neurovascular device company specializing in intracranial stents, flow diverters, and coil systems for aneurysm treatment. It is a direct regional competitor to Phenox in Europe, with comparable CE Mark product portfolios.

Regional players

• Balt: Balt is a French-based neurovascular and interventional neuroradiology device manufacturer with a broad portfolio of coils, stents, and flow diverters. It is a comparable European regional player serving similar CE Mark markets to Phenox.

Broad incumbents

• Stryker (Neurovascular): Stryker's Neurovascular division (formed via the Concentric Medical and Codman Neuro acquisitions) offers stent retrievers, aspiration catheters, and coils. It is a broad incumbent competitor to Phenox in stroke intervention and aneurysm treatment.
• MicroPort Scientific (Neurovascular): MicroPort's neurovascular division, formed through acquisition of Stryker's Neurovascular business, competes with Phenox in flow diversion and stent retriever markets globally. It serves as a broad incumbent with FDA-approved products across major geographies.
• Johnson & Johnson (Cerenovus): Cerenovus is Johnson & Johnson's neurovascular division, offering stent retrievers, coils, flow diverters, and embolization products. As a broad incumbent, it competes with Phenox across the full neurointerventional procedure workflow with significant R&D and commercial resources.
• Medtronic (Neurovascular): Medtronic, through its acquisition of Covidien and the Solitaire stent retriever franchise, is a global incumbent in the neurovascular devices market. It competes with Phenox across thrombectomy, flow diversion, and aneurysm treatment with FDA-approved products and broad hospital coverage.

Emerging players

• MIVI Neuroscience: MIVI Neuroscience develops innovative stroke treatment devices including aspiration catheters and stent retrievers. As a smaller, focused neurovascular player, it competes with Phenox's pRESET line in the mechanical thrombectomy segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/phenox_neuro
• YouTubeyoutube.com/channel/UCz5bCLOwnQ6Bf-mmMUbBX3A
• LinkedInlinkedin.com/company/phenox-gmbh

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phenox